CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT00500344
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD

Key Dates

First listed
Jul 12, 2007
Start date
Jul 31, 2007
Status verified
Apr 2018
Primary completion
Mar 31, 2009
Completion
Mar 31, 2009

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: 1

Primary Outcome Measure

To determine if there is an improvement in retinal function determined by the ERG following treatment with ranibizumab [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington UniversitySt LouisMissouri63110-

Find similar trials in St Louis, MO

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Washington University· St Louis, MO

Related Studies